Denosumab Associated with Dermatologic Toxicity – FDA Adverse Events Reporting System

At the May 2012 Annual Meeting of the Society-for-Investigative-Dermatology, one of the presentations, entitled “Denosumab is associated with dermatologic toxicity in the FDA-Adverse Events Reporting System (AERS) database,” discussed reports of “cutaneous ([skin] adverse events” (CAE) reported to the FDA’s Read on! →

Denosumab (aka Prolia, Xgeva) – Even Worse than the Bisphosphonates?

Like the bisphosphonates, denosumab (trade names Prolia, Xgeva)[i] also prevents osteoclasts from removing old, damaged or worn out bone. It just does so via a different action than the bisphosphonates — an action that may turn out to have even Read on! →